Periostin in middle ear mucosa according to eosinophilic otitis media severity: Middle ear pathology-based treatment.


Journal

Auris, nasus, larynx
ISSN: 1879-1476
Titre abrégé: Auris Nasus Larynx
Pays: Netherlands
ID NLM: 7708170

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 14 02 2020
revised: 01 05 2020
accepted: 27 05 2020
pubmed: 27 6 2020
medline: 15 7 2021
entrez: 27 6 2020
Statut: ppublish

Résumé

Eosinophilic otitis media (EOM) is an intractable disorder associated with bronchial asthma and chronic rhinosinusitis with nasal polyposis. Periostin is an extracellular matrix protein secreted by fibroblasts in response to interleukin (IL)-4 and/or IL-13 and is a known marker for eosinophilic disorders. We assessed serum periostin levels and expression of periostin in the middle ear mucosa according to three grade of EOM severity (grade1 to 3). 68 patients of blood and serum samples were corrected by whom diagnose bilateral EOM in Jichi Medical University Saitama Medical Center from January 2015 to June 2017.Immunohistochemical evaluation was performed to 18 EOM middle ears mucosa samples, which cauterized in tree groups and compared to that of chronic otitis media (COM). Serum periostin levels was significantly higher in EOM patients than in COM patients (EOM, 125.0 ± 45.5 ng/mL; COM, 79.4 ± 38.3 ng/mL; P<0.0001). The expression of periostin immunopositivity in the EOM middle ear mucosa was significantly greater in severe cases (grade3 samples) than others (grade1 and grade2 samples) (P <0.001 and P = 0.011, respectively). Periostin was expressed at the lamina propria especially in severe EOM cases and the cases had little response to glucocorticoids treatment. This study showed that periostin in the middle ear mucosa was correlated with EOM severity, and EOM with highly expressed periostin had difficulty in glucocorticoids treatment.

Identifiants

pubmed: 32586742
pii: S0385-8146(20)30134-6
doi: 10.1016/j.anl.2020.05.014
pii:
doi:

Substances chimiques

Cell Adhesion Molecules 0
Glucocorticoids 0
POSTN protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

527-535

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Auteurs

Yoshihiko Esu (Y)

Department of Otolaryngology, Jichi Medical University Saitama Medical Center, 1-847 Amanuma, Saitama 330-8503, Japan.

Maria Masuda (M)

Department of Otolaryngology, Jichi Medical University Saitama Medical Center, 1-847 Amanuma, Saitama 330-8503, Japan.

Naohiro Yoshida (N)

Department of Otolaryngology, Jichi Medical University Saitama Medical Center, 1-847 Amanuma, Saitama 330-8503, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH